[1]
|
Matos, T.R., O’Malley, J.T., Lowry, E.L., et al. (2017) Clinically Resolved Psoriatic Lesions Contain Psoriasis-Specific IL-17-Producing αβ T Cell Clones. Journal of Clinical Investigation, 127, 4031-4041.
https://doi.org/10.1172/JCI93396
|
[2]
|
Brembilla, N.C., Senra, L. and Boehncke, W.H. (2018) The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Frontiers in Immunology, 9, 1682. https://doi.org/10.3389/fimmu.2018.01682
|
[3]
|
Yang, D., Chen, X., Wang, J., Lou, Q., et al. (2019) Dysregulated Lung Commensal Bacteria Drive Interleukin-17B Production to Promote Pulmonary Fibrosis through Their Outer Mem-brane Vesicles. Immunity, 50, 692-706.
https://doi.org/10.1016/j.immuni.2019.02.001
|
[4]
|
Lee, Y., Clinton, J., Yao, C. and Chang, S.H. (2019) Interleu-kin-17D Promotes Pathogenicity during Infection by Suppressing CD8 T Cell Activity. Frontiers in Immunology, 10, 1172. https://doi.org/10.3389/fimmu.2019.01172
|
[5]
|
Yan, X., Tu, H., Liu, Y., Chen, T. and Cao, J. (2020) Inter-leukin-17D Aggravates Sepsis by Inhibiting Macrophage Phagocytosis. Critical Care Medicine, 48, e58-e65. https://doi.org/10.1097/CCM.0000000000004070
|
[6]
|
Xu, M. and Dong, C. (2017) IL-25 in Allergic Inflamma-tion. Immunological Reviews, 278, 185-191.
https://doi.org/10.1111/imr.12558
|
[7]
|
Liu, Y., Lagowski, J.P., Gao, S., Raymond, J.H., White, C.R. and Ku-lesz-Martin, M.F. (2010) Regulation of the Psoriatic Chemokine CCL20 by E3 Ligases trim32 and Piasy in Keratinocytes. Journal of Investigative Dermatology, 130, 1384-1390. https://doi.org/10.1038/jid.2009.416
|
[8]
|
Ha, H.L., Wang, H., Pisitkun, P., et al. (2014) IL-17 Drives Psoriatic Inflammation via Distinct, Target Cell-Specific Mechanisms. Pro-ceedings of the National Academy of Sciences of the United States of America, 111, e3422-e3431.
https://doi.org/10.1073/pnas.1400513111
|
[9]
|
Carrier, Y., Ma, H.L., Ramon, H.E., et al. (2011) Inter-Regulation of Th17 Cytokines and the IL-36 Cytokines in Vitro and in Vivo: Implications in Psoriasis Pathogenesis. Journal of In-vestigative Dermatology, 131, 2428-2437.
https://doi.org/10.1038/jid.2011.234
|
[10]
|
Michalek, I.M., Loring, B. and John, S.M. (2017) A Systematic Review of Worldwide Epidemiology of Psoriasis. Journal of the European Academy of Dermatology and Venereology, 31, 205-212. https://doi.org/10.1111/jdv.13854
|
[11]
|
Fotiadou, C., Lazaridou, E., Sotiriou, E., et al. (2015) IL-17A, IL22, and IL-23 as Markers of Psoriasis Activity: A Cross-Sectional, Hospital-Based Study. Journal of Cutaneous Med-icine and Surgery, 19, 555-560.
https://doi.org/10.1177/1203475415584503
|
[12]
|
Nanda, H., Ponnusamy, N., Odumpatta, R., et al. (2020) Explor-ing Genetic Targets of Psoriasis Using Genome Wide Association Studies (GWAS) for Drug Repurposing. 3 Biotech, 10, 43. https://doi.org/10.1007/s13205-019-2038-4
|
[13]
|
Gutowska-Owsiak, D., Schaupp, A.L., Salimi, M., et al. (2012) IL-17 Downregulates Filaggrin and Affects Keratinocyte Expression of Genes Associated with Cellular Adhesion. Experimental Dermatology, 21, 104-110.
https://doi.org/10.1111/j.1600-0625.2011.01412.x
|
[14]
|
Iznardo, H. and Puig, L. (2021) Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. International Journal of Molecular Sciences, 22, 4344. https://doi.org/10.3390/ijms22094344
|
[15]
|
Soderstrom, C., Berstein, G., Zhang, W., et al. (2017) Ultra-Sensitive Measurement of IL-17A and IL-17F in Psoriasis Patient Serum and Skin. The AAPS Journal, 19, 1218-1222. https://doi.org/10.1208/s12248-017-0094-4
|
[16]
|
Fujishima, S., Watanabe, H., Kawaguchi, M., et al. (2010) In-volvement of IL-17F via the Induction of IL-6 in Psoriasis. Archives of Dermatological Research, 302, 499-505. https://doi.org/10.1007/s00403-010-1033-8
|
[17]
|
Senra, L., Stalder, R., Alvarez Martinez, D., Chizzolini, C., Boehncke, W.H. and Brembilla, N.C. (2016) Keratinocyte-Derived IL-17E Contributes to Inflammation in Psoriasis. Journal of Investigative Dermatology, 136, 1970-1980.
https://doi.org/10.1016/j.jid.2016.06.009
|
[18]
|
Ong, X., Zhu, S., Shi, P., et al. (2011) IL-17RE Is the Functional Receptor for IL17C and Mediates Mucosal Immunity to Infection with Intestinal Pathogens. Nature Immunology, 12, 1151-1158. https://doi.org/10.1038/ni.2155
|
[19]
|
Xu, M., Lu, H., Lee, Y.H., et al. (2018) An Interleu-kin-25-Mediated Autoregulatory Circuit in Keratinocytes Plays a Pivotal Role in Psoriatic Skin Inflammation. Immunity, 48, 787-798.e4. https://doi.org/10.1016/j.immuni.2018.03.019
|
[20]
|
López-Ferrer, A., Vilarrasa, E. and Puig, L. (2015) Secukinumab (AIN457) for the Treatment of Psoriasis. Expert Review of Clinical Immunology, 11, 1177-1188. https://doi.org/10.1586/1744666X.2015.1095092
|
[21]
|
Papp, K.A., Leonardi, C.L., Blauvelt, A., Reich, K., Korman, N.J., Ohtsuki, M., Paul, C., Ball, S., Cameron, G.S., Erickson, J., et al. (2018) Ixekizumab Treatment for Psoriasis: Inte-grated Efficacy Analysis of Three Double-Blinded, Controlled Studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). British Journal of Dermatology, 178, 674-681.
https://doi.org/10.1111/bjd.16050
|
[22]
|
Papp, K.A., Merola, J.F., Gottlieb, A.B., Griffiths, C.E.M., et al. (2018) Dual Neutralization of both Interleukin 17A and Interleukin 17F with Bimekizumab in Patients with Psoriasis: Results from BE ABLE 1, a 12-Week Randomized, Double-Blinded, Placebo-Controlled Phase 2b Trial. Journal of the American Academy of Dermatology, 79, 277- 286e10. https://doi.org/10.1016/j.jaad.2018.03.037
|
[23]
|
Sabat, R., Jemec, G.B.E., Matusiak, Ł., Kimball, A.B., Prens, E. and Wolk, K. (2020) Hidradenitis Suppurativa. Nature Reviews Disease Primers, 6, 18. https://doi.org/10.1038/s41572-020-0149-1
|
[24]
|
Vinkel, C. and Thomsen, S.F. (2018) Hidradenitis Suppurativa: Causes, Features, and Current Treatments. Journal of Clinical and Aesthetic Dermatology, 11, 17-23.
|
[25]
|
Constantinou, C.A., Fragoulis, G.E. and Nikiphorou, E. (2019) Hidradenitis Suppurativa: Infection, Auto-immunity, or Both? Therapeutic Advances in Musculoskeletal Disease, 11. https://doi.org/10.1177/1759720X19895488
|
[26]
|
Del Duca, E., Morelli, P., Bennardo, L., Di Raimondo, C. and Nisticò, S.P. (2020) Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa. International Journal of Molecular Sciences, 21, 8436.
https://doi.org/10.3390/ijms21228436
|
[27]
|
Wolk, K., Join‐Lambert, O. and Sabat, R. (2020) Aetiology and Patho-genesis of Hidradenitis Suppurativa. British Journal of Dermatology, 183, 999-1010. https://doi.org/10.1111/bjd.19556
|
[28]
|
Prussick, L., Rothstein, B., Joshipura, D., et al. (2019) Open-Label, Inves-tigator-Initiated, Single-Site Exploratory Trial Evaluating Secukinumab, an Anti-Interleukin-17A Monoclonal Antibody, for Patients with Moderate-to-Severe Hidradenitis Suppurativa. British Journal of Dermatology, 181, 609-611. https://doi.org/10.1111/bjd.17822
|
[29]
|
Frew, J.W., Navrazhina, K., Grand, D., et al. (2020) The Effect of Subcuta-neous Brodalumab on Clinical Disease Activity in Hidradenitis Suppurativa: An Open-Label Cohort Study. Journal of the American Academy of Dermatology, 83, 1341-1348. https://doi.org/10.1016/j.jaad.2020.05.007
|
[30]
|
Maverakis, E., Marzano, A.V., Le, S.T., et al. (2020) Pyoderma Gangrenosum. Nature Reviews Disease Primers, 6, 81.
https://doi.org/10.1038/s41572-020-0213-x
|
[31]
|
Ahn, C., Negus, D. and Huang, W. (2018) Pyoderma Gangreno-sum: A Review of Pathogenesis and Treatment. Expert Review of Clinical Immunology, 14, 225-233. https://doi.org/10.1080/1744666X.2018.1438269
|
[32]
|
Caproni, M., Antiga, E., Volpi, W., et al. (2015) The Treg/Th17 Cell Ratio Is Reduced in the Skin Lesions of Patients with Pyoderma Gangrenosum. British Journal of Der-matology 173, 275-278. https://doi.org/10.1111/bjd.13670
|
[33]
|
Marzano, A.V., Damiani, G., Ceccherini, I., Berti, E., Gattorno, M. and Cugno, M. (2017) Autoinflammation in Pyoderma Gangrenosum and Its Syndromic Form (Pyo-derma Gangrenosum, Acne and Suppurative Hidradenitis). British Journal of Dermatology 176, 1588-1598. https://doi.org/10.1111/bjd.15226
|
[34]
|
Lauffer, F., Seiringer, P., Böhmer, D., Oesterlin, C. and Eyerich, K. (2021) 044 Safety and Efficacy of Anti-IL-17 (Secukinumab) for the Treatment of Pyoderma Gangrenosum. Journal of Investi-gative Dermatology, 141, S156.
https://doi.org/10.1016/j.jid.2021.08.046
|
[35]
|
Feldmeyer, L., Mylonas, A., Demaria, O., et al. (2017) Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris. JAMA Dermatology, 153, 304-308. https://doi.org/10.1001/jamadermatol.2016.5384
|
[36]
|
Napolitano, M., Abeni, D. and Didona, B. (2018) Biologics for Pityriasis Rubra Pilaris Treatment: A Review of the Literature. Journal of the American Academy of Dermatology, 79, 353-359.e11.
https://doi.org/10.1016/j.jaad.2018.03.036
|
[37]
|
Schuster, D., Pfister-Wartha, A., Bruckner-Tuderman, L. and Schempp, C.M. (2016) Successful Treatment of Refractory Pityriasis Rubra Pilaris with Secukinumab. JAMA Derma-tology, 152, 1278-1280.
https://doi.org/10.1001/jamadermatol.2016.3885
|
[38]
|
Hughes, M., Allanore, Y., Chung, L., et al. (2020) Raynaud Phenomenon and Digital Ulcers in Systemic Sclerosis. Nature Reviews Rheumatology, 16, 208-221. https://doi.org/10.1038/s41584-020-0386-4
|
[39]
|
Cutolo, M., Soldano, S. and Smith, V. (2019) Pathophysiology of Systemic Sclerosis: Current Understanding and New Insights. Expert Review of Clinical Immunology, 15, 753-7640. https://doi.org/10.1080/1744666X.2019.1614915
|
[40]
|
Gonçalves, R.S.G., Pereira, M.C., Dantas, A.T., et al. (2018) IL-17 and Related Cytokines Involved in Systemic Sclerosis: Perspectives. Autoimmunity, 51, 1-9. https://doi.org/10.1080/08916934.2017.1416467
|
[41]
|
Gonçalves, R.S.G., Pereira, M.C., Dantas, A.T., Almeida, A.R., Rego, M., Lima, E.A., et al. (2019) CCL3, IL-7, IL-13 and IFNg Transcripts Are Increased in Skin’s Biopsy of Systemic Sclerosis. Experimental Dermatology, 28, 1172-1175.
https://doi.org/10.1111/exd.13982
|
[42]
|
Yang, X., Yang, J., Xing, X., Wan, L. and Li, M. (2014) Increased Fre-quency of Th17 Cells in Systemic Sclerosis Is Related to Disease Activity and Collagen Overproduction. Arthritis Re-search & Therapy, 16, R4.
https://doi.org/10.1186/ar4430
|
[43]
|
Liu, M., Yang, J., Xing, X., Cui, X. and Li, M. (2014) Interleukin-17A Pro-motes Functional Activation of Systemic Sclerosis Patient-Derived Dermal Vascular Smooth Muscle Cells by Extracellu-lar-Regulated Protein Kinases Signalling Pathway. Arthritis Research & Therapy, 16, 4223. https://doi.org/10.1186/s13075-014-0512-2
|
[44]
|
Luchsinger, I., Knöpfel, N., Theiler, M., et al. (2020) Secuki-numab Therapy for Netherton Syndrome. JAMA Dermatology, 156, 907-911. https://doi.org/10.1001/jamadermatol.2020.1019
|
[45]
|
Atwa, M.A., Youssef, N. and Bayoumy, N.M. (2016) T-Helper 17 Cytokines (Interleukins 17, 21, 22, and 6, and Tumor Necrosis Factor-a) in Patients with Alopecia Areata: Association with Clinical Type and Severity. International Journal of Dermatology, 55, 666-672. https://doi.org/10.1111/ijd.12808
|
[46]
|
Han, Y.M., Sheng, Y.Y., Xu, F., Qi, S.S., Liu, X.J., Hu, R.M., et al. (2015) Imbalance of T-Helper 17 and Regulatory T Cells in Patients with Alopecia Areata. The Journal of Dermatology, 42, 981-988.
https://doi.org/10.1111/1346-8138.12978
|
[47]
|
Ortolan, L.S., Kim, S.R., Crotts, S., et al. (2019) IL-12/IL-23 Neu-tralization Is Ineffective for Alopecia Areata in Mice and Humans. The Journal of Allergy and Clinical Immunology, 144, 1731-1734.e1.
https://doi.org/10.1016/j.jaci.2019.08.014
|
[48]
|
Suárez-Fariñas, M., Ungar, B., Correa da Rosa, J., Ewald, D.A., Rozenblit, M., Gonzalez, J., Xu, H., Zheng, X., Peng, X., Estrada, Y.D., Dillon, S.R., Krueger, J.G. and Guttman-Yassky, E. (2015) RNA Sequencing Atopic Dermatitis Transcriptome Profiling Provides Insights into Novel Disease Mechanisms with Potential Therapeutic Implications. Journal of Allergy and Clinical Immunology, 135, 1218-1227. https://doi.org/10.1016/j.jaci.2015.03.003
|
[49]
|
Vakharia, P.P. and Silverberg, J.I. (2018) New Thera-pies for Atopic Dermatitis: Additional Treatment Classes. Journal of the American Academy of Dermatology, 78, S76-S83. https://doi.org/10.1016/j.jaad.2017.12.024
|